CA
NZ
UK
AU
IND
US
…
Cofinimmo SA properties for more than 40 years. The company has a portfolio spread across Belgium, France, the Netherlands, Germany, Spain, Finland, Ireland, Italy and the United Kingdom, with a value of approximately 6.1 billion EUR. Responding to societal changes, Cofinimmo's mission is to provide high-quality care, living, and working spaces to partner-tenants that directly benefit their occupants. (Caring, Living and Working Together in Real Estate is the expression of this mission). Thanks to its expertise, Cofinimmo has assembled a healthcare real estate portfolio of approximately 4.7 billion EUR in Europe. As an independent company that applies the highest standards of corporate governance and sustainability, Cofinimmo offers its tenants services and manages its portfolio through a team of approximately 150 employees in Brussels, Paris, Breda, Frankfurt and Madrid. Cofinimmo is listed on Euronext Brussels (BEL20) and benefits from the REIT system in Belgium (RREC), in France (SIIC), in Spain (SOCIMI) and in the United Kingdom (UK-REIT). Its activities are supervised by the Financial Services and Markets Authority (FSMA), the Belgian regulator. Cofinimmo SA was incorporated in 1983 in Belgium.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Cofinimmo SA/NV is a Belgian-listed real estate investment company with a portfolio focused on healthcare properties, offices and other rental assets in Western Europe. Long-term growth may be supported by aging demographics boosting demand for healthcare real estate, contracted rents from long-term leases and geographic diversification, which could make cash flows relatively predictable.
Material risks include sensitivity to higher interest rates and property valuations, tenant concentration and regulatory changes in healthcare funding, as well as leverage and liquidity pressure.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 227.61M | 80.35M | -47.13M | 494.05M | 275.49M |
| Minority interest | -5.06M | -9.26M | -1.32M | 0.37M | -2.67M |
| Net income | 213.38M | 63.89M | -55.50M | 482.94M | 260.34M |
| Selling general administrative | - | 3.94M | 4.53M | 13.80M | 3.66M |
| Selling and marketing expenses | - | 0.22M | 0.27M | 0.27M | 0.19M |
| Gross profit | 299.25M | 300.24M | 291.93M | 281.36M | 262.85M |
| Reconciled depreciation | - | 1.86M | 2.55M | 3.19M | 1.42M |
| Ebit | - | 158.56M | 27.89M | 347.22M | 263.25M |
| Ebitda | 265.18M | 160.41M | 30.44M | 350.42M | 264.67M |
| Depreciation and amortization | - | 1.86M | 2.55M | 3.19M | 1.42M |
| Operating income | 277.84M | 286.82M | 66.50M | 299.55M | 248.88M |
| Other operating expenses | 71.77M | 108.63M | 118.79M | 109.35M | 114.16M |
| Interest expense | 37.57M | 39.53M | 39.55M | 33.35M | 20.66M |
| Tax provision | - | 7.20M | 6.18M | 11.49M | 12.49M |
| Interest income | 13.46M | 12.66M | 13.33M | 11.50M | 12.12M |
| Net interest income | -25.48M | -28.09M | -27.48M | -23.24M | -9.60M |
| Income tax expense | 9.17M | 7.20M | 7.04M | 11.49M | 12.49M |
| Total revenue | 349.62M | 395.46M | 396.49M | 366.42M | 340.81M |
| Total operating expenses | 21.41M | 13.42M | 14.22M | 24.29M | 36.20M |
| Cost of revenue | 50.36M | 95.21M | 104.57M | 85.06M | 77.96M |
| Total other income expense net | -50.23M | -60.25M | -113.63M | 194.50M | 26.62M |
| Net income from continuing ops | 218.42M | 73.15M | -54.17M | 482.57M | 263.00M |
| Net income applicable to common shares | - | - | - | 482.94M | 260.34M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 6435.49M | 6440.05M | 6691.42M | 6803.57M | 6176.95M |
| Intangible assets | 1.49M | 1.81M | 2.13M | 2.37M | 2.49M |
| Other current assets | - | 65.86M | 105.32M | 0.00M | 8.93M |
| Total liab | 2846.74M | 2825.61M | 2992.44M | 3136.57M | 2889.42M |
| Total stockholder equity | 3509.97M | 3534.99M | 3623.26M | 3637.41M | 3233.27M |
| Other current liab | - | 63.74M | 64.67M | 22.46M | 125.37M |
| Common stock | 2040.76M | 2041.52M | 1970.21M | 1761.87M | 1698.52M |
| Capital stock | 2041.52M | 2041.52M | 1970.21M | 1761.87M | 1698.52M |
| Retained earnings | 213.46M | 63.89M | 362.55M | 482.94M | 260.34M |
| Other liab | - | - | - | 99.65M | 93.92M |
| Good will | 0.00M | 0.00M | 0.00M | 27.34M | 41.63M |
| Other assets | - | 0.00M | - | 183.13M | 166.29M |
| Cash | 23.77M | 25.80M | 19.96M | 19.61M | 19.86M |
| Total current liabilities | 999.32M | 971.01M | 1100.92M | 1034.94M | 1272.99M |
| Current deferred revenue | - | - | 19.09M | 22.44M | 126.15M |
| Net debt | 2563.49M | 2561.53M | 1564.19M | 2860.93M | 2545.02M |
| Short term debt | 999.32M | 834.07M | 953.19M | 880.05M | 1100.97M |
| Short long term debt | 999.70M | 834.07M | 953.19M | 880.05M | 1100.97M |
| Short long term debt total | 2587.26M | 2587.34M | 1584.15M | 2880.54M | 2564.88M |
| Other stockholder equity | 1469.21M | 1429.58M | 895.77M | 1392.60M | 1274.42M |
| Property plant equipment | - | - | - | 6084.90M | 5672.01M |
| Total current assets | 207.91M | 136.16M | 178.50M | 245.38M | 191.42M |
| Net tangible assets | - | - | - | 3607.70M | 3189.16M |
| Short term investments | 1.08M | 2.07M | 0.64M | 0.64M | - |
| Net receivables | 184.15M | 42.43M | 53.22M | 82.42M | 72.06M |
| Long term debt | 1588.54M | 1753.27M | 1791.33M | 2000.48M | 1463.07M |
| Inventory | - | - | -0.64M | - | - |
| Accounts payable | 126.34M | 46.74M | 55.75M | 132.42M | 46.65M |
| Accumulated other comprehensive income | - | 170.45M | 394.73M | - | - |
| Non currrent assets other | 113.80M | 6156.67M | 175.48M | 6246.54M | 5935.48M |
| Non current assets total | 6227.58M | 6303.88M | 6512.92M | 6558.18M | 5985.53M |
| Capital lease obligations | 0.00M | 0.00M | 0.00M | 0.91M | 0.84M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | 96.98M | 13.59M | -334.39M | -9.49M |
| Change to liabilities | - | - | - | -9.43M | -3.35M |
| Total cashflows from investing activities | -31.79M | 96.98M | 13.59M | -334.39M | -745.44M |
| Net borrowings | - | -158.12M | -218.47M | 301.44M | 485.33M |
| Total cash from financing activities | -242.36M | -370.31M | -241.12M | 123.72M | 516.21M |
| Change to operating activities | - | - | - | -0.63M | -4.96M |
| Net income | 213.38M | 63.89M | -55.50M | 482.94M | 260.34M |
| Change in cash | 1.03M | 5.84M | 0.35M | -0.25M | -28.79M |
| Begin period cash flow | 22.73M | 19.96M | 19.61M | 19.86M | 48.64M |
| End period cash flow | 23.77M | 25.80M | 19.96M | 19.61M | 19.86M |
| Total cash from operating activities | 272.08M | 279.17M | 227.88M | 210.42M | 200.44M |
| Issuance of capital stock | - | 0.20M | 165.07M | 0.53M | 178.82M |
| Depreciation | - | 1.86M | 2.55M | 3.19M | 1.42M |
| Other cashflows from investing activities | 11.29M | 87.15M | 115.50M | -0.79M | -17.09M |
| Dividends paid | 236.46M | 153.41M | 160.09M | -134.96M | -107.09M |
| Change to account receivables | 17.62M | 3.44M | -0.12M | -4.00M | -4.57M |
| Sale purchase of stock | - | - | - | 275.21M | - |
| Other cashflows from financing activities | -5.58M | -58.97M | -27.64M | 292.12M | 444.49M |
| Change to netincome | - | - | - | -259.08M | -45.84M |
| Capital expenditures | 0.30M | 0.41M | 1.29M | 1.27M | 1.52M |
| Change in working capital | 21.62M | 6.91M | -36.52M | -15.18M | -15.22M |
| Other non cash items | 37.08M | 206.52M | 317.34M | -260.53M | -46.09M |
| Free cash flow | 271.78M | 278.76M | 226.59M | 209.15M | 198.92M |
Sector: Real Estate Industry: REIT - Healthcare Facilities
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| WELL Welltower Inc |
0.48 0.21% |
227.20 | 170.68 | 72.46 | 7.75 | 2.13 | 9.77 | 27.67 |
| VTR Ventas Inc |
-2.27 2.72% |
81.07 | 161.02 | 131.58 | 7.08 | 3.12 | 9.07 | 24.46 |
| OHI Omega Healthcare Investors Inc |
-0.49 1.06% |
45.64 | 16.83 | 10.13 | 11.78 | 2.66 | 14.30 | 12.72 |
| DOC Healthpeak Properties Inc |
-0.47 2.47% |
18.55 | 164.70 | 113.64 | 4.06 | 1.58 | 7.64 | 13.08 |
Cofinimmo SA properties for more than 40 years. The company has a portfolio spread across Belgium, France, the Netherlands, Germany, Spain, Finland, Ireland, Italy and the United Kingdom, with a value of approximately 6.1 billion EUR. Responding to societal changes, Cofinimmo's mission is to provide high-quality care, living, and working spaces to partner-tenants that directly benefit their occupants. (Caring, Living and Working Together in Real Estate is the expression of this mission). Thanks to its expertise, Cofinimmo has assembled a healthcare real estate portfolio of approximately 4.7 billion EUR in Europe. As an independent company that applies the highest standards of corporate governance and sustainability, Cofinimmo offers its tenants services and manages its portfolio through a team of approximately 150 employees in Brussels, Paris, Breda, Frankfurt and Madrid. Cofinimmo is listed on Euronext Brussels (BEL20) and benefits from the REIT system in Belgium (RREC), in France (SIIC), in Spain (SOCIMI) and in the United Kingdom (UK-REIT). Its activities are supervised by the Financial Services and Markets Authority (FSMA), the Belgian regulator. Cofinimmo SA was incorporated in 1983 in Belgium.
| Name | Title | Year Born |
|---|---|---|
| Mr. Jean-Pierre Hanin | Interim COO, MD, CEO & Director | 1966 |
| Mr. Jean Kotarakos | CFO & Exec. Director | 1973 |
| Ms. Francoise Roels | Chief of Corp. Affairs, Sec. Gen., Compliance Officer & Exec. Director | 1961 |
| Mr. Sebastien Berden | Chief Operating Officer of Healthcare | NA |
| Ms. Yeliz Bicici | Chief Operating Officer Offices & Real Estate Devel. | NA |
| Ms. Pascale Minet | Head of Accounting | NA |
| Ms. Ellen Grauls | Head of External Communication & Investor Relations | NA |
| Steven Aernoudt | Head of HR & Internal Communication | NA |
| Mr. Jean Van Buggenhout | Head of Property Services | NA |
| Mr. Domien Szeker | Head of Project Management | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.02%
Communication Services
-0.63%
Consumer Cyclical
-0.11%
Consumer Defensive
-0.45%
Energy
+0.39%
Financial Services
-0.10%
Financials
-0.81%
Healthcare
+1.03%
Industrials
+0.32%
Real Estate
-0.31%
Technology
+0.59%
Utilities
-0.18%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...